Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ages 19 to 45 inclusive~* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations~* Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI = weight (kg)/ \[height (m)\]2~Exclusion Criteria:~* Women of child-bearing potential (WOCBP) who are unwilling or unable to use acceptable barrier methods (condoms and spermicides) to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product~* Any significant acute or chronic medical illness~* Current or recent (within 3 months) gastrointestinal disease~* Any major surgery within 4 weeks of study drug administration~* History of allergy to Dipeptidyl peptidase 4 (DPP4) inhibitor or related compounds~* History of allergy or intolerance to metformin or other similar acting agents~* Prior exposure to saxagliptin~* Prior exposure to metformin within 3 months of study drug administration.~* Estimated creatinine clearance (Clcr) of \< 80ml/min using the Cockcroft Gault formula

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed) (Type: EXPERIMENTAL): Participants were randomized to receive oral co-administration of a 2.5 mg tablet of saxagliptin plus a 500 mg tablet of metformin immediate release (IR) under fasted conditions (S + M \[fasted\]) followed by a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions (S/M \[fed\]) followed by S/M under fasting conditions (S/M \[fasted\]) followed by S + M under fed conditions (S + M \[fed\])
- S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed) (Type: EXPERIMENTAL): Participants were randomized to receive S/M (fasted) followed by S + M (fasted) followed by S + M (fed) followed by S/M (fed)
- S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted) (Type: EXPERIMENTAL): Participants were randomized to receive S + M (fed) followed by S/M (fasted) followed by S/M (fed) followed by S+M (fasted)
- S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted) (Type: EXPERIMENTAL): Participants were randomized to receive S/M (fed) followed by S+M (fed) followed by S+M (fasted) followed by S/M (fasted)

Based on this trial design, predict the completion outcome and termination type (if applicable).